Last edition
News about "licensing agreement"
Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma
Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.
Licensing Agreement | 17/12/2025 | By News Bureau
Actimed Therapeutics Announces Licensing Agreement with Mankind Pharma
Actimed Therapeutics has entered into an exclusive licensing agreement with Mankind Pharma for S-pindolol, its novel therapy in development for cancer cachexia. The partnership marks a step toward delivering the first globally approved treatment for this debilitating condition to patients across India and South Asia.
Licensing Agreement | 21/11/2025 | By Dineshwori
Ocugen and Kwangdong Finalise OCU400 Gene Therapy Deal for Retinitis Pigmentosa in Korea
Pursuant to the licence agreement, Ocugen will receive upfront license fees and near-term development milestones equaling up to USD 7.5 million. The company will be entitled to sales milestones of USD 1.5 million for every USD 15 million of sales in Korea, projected to reach USD 180 million or more in the first 10 years of commercialisation.
Licensing Agreement | 17/09/2025 | By Dineshwori | 279
Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against the collaboration targets.
Licensing Agreement | 05/01/2024 | By Manvi | 484
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy